Holen Sie sich die Stockscreener-App
1.928
0.10%
-0.002
Handel nachbörslich:
2.25
0.322
+16.70%
Schlusskurs vom Vortag:
$1.93
Offen:
$1.94
24-Stunden-Volumen:
442.77K
Relative Volume:
1.58
Marktkapitalisierung:
$47.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.76M
KGV:
-2.0731
EPS:
-0.93
Netto-Cashflow:
-
1W Leistung:
-2.63%
1M Leistung:
-17.96%
6M Leistung:
+76.88%
1J Leistung:
+150.36%
1-Tages-Spanne:
$1.825
$1.95
1-Wochen-Bereich:
$1.825
$2.07
52-Wochen-Spanne:
$0.5985
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie NRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.928 | 47.50M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
What drives NeuroSense Therapeutics Ltd. Equity Warrant stock priceHigh-octane gains - jammulinksnews.com
NeuroSense Therapeutics Ltd. Equity Warrant Stock Analysis and ForecastFree Bull & Bear Market Updates - jammulinksnews.com
What analysts say about NeuroSense Therapeutics Ltd. stockUnprecedented market success - jammulinksnews.com
NeuroSense Therapeutics Ltd. Stock Analysis and ForecastMassive wealth growth - jammulinksnews.com
Is NeuroSense Therapeutics Ltd. Equity Warrant a good long term investmentBreakthrough wealth creation - jammulinksnews.com
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community - PR Newswire
Why NeuroSense Therapeutics Ltd. Equity Warrant stock attracts strong analyst attentionStable Stocks With High Yield - Newser
What drives NeuroSense Therapeutics Ltd. stock priceDouble-digit growth - jammulinksnews.com
How NeuroSense Therapeutics Ltd. Equity Warrant stock performs during market volatilityROI Driven Alerts - Newser
Is NeuroSense Therapeutics Ltd. a good long term investmentFree Stock Selection - Autocar Professional
What analysts say about NeuroSense Therapeutics Ltd. Equity Warrant stockTriple-digit profit margins - Autocar Professional
how neurosense therapeutics ltd. stock performs during market volatilityFree Access to Stock Community - Newser
What makes NeuroSense Therapeutics Ltd. Equity Warrant stock price move sharplyTrade Ready Signal - Newser
How NeuroSense Therapeutics Ltd. stock performs during market volatilityFree Long-Term Wealth Growth Plan - Newser
What makes NeuroSense Therapeutics Ltd. stock price move sharplyMassive Profit Potential - Newser
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionFree Premium Stock Market Reports - Newser
D. Boral Capital Reaffirms Buy Rating for NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense Therapeutics Releases Q2 2025 Corporate Update - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading 0.5% Higher – Here’s What Happened - Defense World
NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval - TipRanks
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):